Oxytocin
also known as Pitocin, OXT, OT
Nine-amino-acid posterior pituitary neuropeptide, FDA-approved for labor induction and lactation augmentation. Modulates oxytocin receptors (OXTR) in hypothalamus, amygdala, and hippocampus, influencing GABAergic, dopaminergic, and serotonergic neurotransmission. Investigated for social cognition deficits in autism spectrum disorder, social anxiety, and schizophrenia. Clinical effects include enhanced social bonding, trust, and gaze behavior; neuromodulatory actions span synaptic plasticity, neurogenesis, and anti-inflammatory pathways.
At a glance
Intranasal · IV (obstetric)
Primary target — Oxytocin receptors (OXTR) — hypothalamus, amygdala, hippocampus, ventral tegmental area.
Pathway — OXTR activation → Gq/11-coupled signaling → modulation of GABAergic, dopaminergic, serotonergic pathways → enhanced synaptic plasticity, neurogenesis, emotional regulation.
Downstream effect — Social bonding enhancement, trust behavior, gaze modulation, reciprocal eye contact, anti-inflammatory and antioxidant neuroprotection, reduced amygdala threat response [paul-2026][prinsen-2026][yuan-2026].
Origin — Endogenous 9-amino-acid peptide synthesized in hypothalamic paraventricular and supraoptic nuclei, released from posterior pituitary [paul-2026].
Feedback intact — Yes — endogenous oxytocin-mediated feedback via central and peripheral OXTR pathways.
| Parameter | Value |
|---|---|
| Intranasal (research — autism, social cognition) | 24–48 IU [prinsen-2026][burmester-2025]Single dose; chronic dosing protocols vary (4–12 weeks documented). |
| Frequency (research) | Once daily to twice daily |
| IV (obstetric — labor induction) | 0.5–2 mU/min, titrated every 30–60 minFDA-approved Pitocin protocol; maximum 20–40 mU/min per institutional guidelines. |
| Evidence basis (social cognition) | Phase 1–2 RCTs in ASD, schizophrenia, social anxiety |
| Evidence basis (obstetric) | FDA-approved · standard-of-care |
| Duration (research protocols) | 4–12 weeks chronic administration [prinsen-2026] |
| Half-life | ~3–20 min (plasma); CNS effects persist longer |
| Timing (intranasal) | Morning or pre-social interactionAcute effects within 30–90 minutes. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
- — Fetal distress or abnormal fetal heart rate patterns (obstetric)
- — Cephalopelvic disproportion
- — Hypersensitivity to oxytocin
- — Severe cardiovascular disease (obstetric use)
- — Hypertonic or hyperactive uterus
- — Prior uterine surgery or cesarean section (relative — use cautiously)
- 01Intranasal (research protocols)
Administer 24–48 IU (typically 3–6 puffs per nostril) using nasal spray device. Patient should be seated, head tilted slightly forward. Avoid sniffing deeply; allow passive absorption.
- 02Timing (intranasal)
Administer 30–90 minutes before anticipated social interaction or cognitive assessment. Acute effects peak within 30–60 minutes.
- 03IV (obstetric — labor induction)
Dilute oxytocin 10 units in 1000 mL isotonic saline. Initiate at 0.5–2 mU/min via infusion pump. Titrate every 30–60 minutes based on contraction pattern and fetal heart rate. Continuous electronic fetal monitoring required.
- 04Storage
Store at 2–8 °C (refrigerated). Do not freeze. Protect from light. Discard if solution is discolored or contains precipitate.
- 05Chronic dosing (research)
Chronic administration protocols (4–12 weeks) documented in pediatric ASD populations. Daily or twice-daily intranasal administration. Safety profile in chronic use still under investigation.
Sources
of 51 rendered claims carry a resolvable citation.
- [burmester-2025]Burmester 2025 — Oxytocin Amplifies Negative Response to Ambiguity in Adolescent Females With and Without Eating Disorders.
journal, 2025 - [chaulagain-2025]Chaulagain 2025 — The neurobiological impact of oxytocin in mental health disorders: a comprehensive review.
journal, 2025 - [paul-2026]Paul 2026 — Oxytocin beyond social bonding: Advancing neuromodulation, synaptic plasticity, and epigenetic precision in CNS disorders.
journal, 2026 - [prinsen-2026]Prinsen 2026 — Impact of chronic oxytocin on gaze and pupil dynamics during live dyadic interactions in children with autism.
journal, 2026 - [tarumi-2026]Tarumi 2026 — Physiological mechanisms of social odor perception and their implications for Autism Spectrum Disorders.
journal, 2026 - [ylmazer-2025]Yılmazer 2025 — Salivary Oxytocin Levels in Children With and Without Autism: Group Similarities and Subgroup Variability.
journal, 2025 - [yuan-2026]Yuan 2026 — The effects of oxytocin on social behavior and eye gaze: Insights from dog-human partnership.
journal, 2026